Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)

Summary

Radiotherapy is a mainstay of treatment in breast cancer treatment, in the adjuvant setting. Radiation dermatitis occurs in up to 65% of these patients; currently, there is no standard of care for this treatment-related toxicity. The aim of this study is to investigate the safety and tolerability (Phase I) and preliminary efficacy (Phase II) of prophylactic esomeprazole cream (termed "Dermaprazole") in patients who require radiation for breast cancer in the adjuvant setting.

Timeline

Start

2023-04-24

Primary completion

2023-06-26

Completion

2024-04-15

Drugs

Indications